Mesa Laboratories, Inc. MLAB

Moby summary of Mesa Laboratories, Inc.'s Q1 2027 earnings call

Adjusted operating income surges nearly 20% as the company returns to core organic growth and strengthens its balance sheet.

LAKEWOOD, Colo., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q27”) ended June 30, 2026 (amounts in thousands). 1Q27 Financial Summary – (comparisons are versus the same prior year period) Revenues increased 1.0%Non-GAAP organic and core organic revenues1 growth was 1.0% and 0.4%,

LAKEWOOD, Colo., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced it will release financial results for its first fiscal quarter (“1Q27”) ended June 30, 2026 following market close on Monday, August 10, 2026. The Company will also hold its first earnings conference call the same day at 4:30 p.m. Eastern Time to

Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2026, to shareholders of record at the close of business on August 31, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality

Mesa Laboratories is priced against a declining genomics drag, while its compliance consumable segment embedded in pharma sterilization mandates earns margins the blended multiple obscures.

In the last week, the United States market has stayed flat, yet it is up 26% over the past year with earnings forecast to grow by 17% annually. In such a robust market environment, identifying stocks trading below their intrinsic value can present unique opportunities for investors seeking potential growth.

LAKEWOOD, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q26”) and fiscal year (“FY26”) ended March 31, 2026 (amounts in thousands). 4Q26 Financial Summary – (comparisons are versus the same prior year period) Revenues increased 2.6%Non-GAAP organic and core organic revenues1

The United States market has experienced a flat week, yet it has shown a robust 27% increase over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this context of growth and stability, identifying stocks that are currently undervalued can offer potential opportunities for investors seeking to capitalize on insider confidence and regional strengths.

Over the last 7 days, the United States market has risen by 4.0%, contributing to a remarkable 39% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In this dynamic environment, identifying good stocks often involves looking for companies that are not only undervalued but also show signs of insider confidence, such as recent buying activity.

LAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens will step down as President and CEO on April 12, 2026, and will enable a smooth leadership transition. “Gary has served as Mesa’s CEO since 2017, leading Mesa through a period of significant growth, expansion into new markets, the maturation

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2025 investor letter. As many believe, US equities experienced solid returns in 2025, with double-digit gains across all major indices, yet underlying conditions revealed extreme volatility and market leadership. A copy of the letter can be downloaded here. In Q4 2025, Conestoga Capital Advisors Small Cap Strategy […]